Auteur T. HORTON

  Tris disponibles Ajouter le résultat à votre sélection

  Affiner la recherche

Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience

L. AMASS ; W. LING ; T. E. FREESE ; C. REIBER ; J. J. ANNON ; A. J. COHEN ; D. McCARTY ; M. S. REID ; L. S. Jr BROWN ; C. CLARK ; ZIEDONIS D. M. ; J. KREJCI ; STINE S. ; T. WINHUSEN ; G. BRIGHAM ; D. BABCOCK ; MUIR J. A. ; B. J. BUCHAN ; T. HORTON | 2004
Dans American Journal on Addictions (Vol.13, Suppl.1, May-June 2004) Article : Périodique

In October 2002, the US Food and Drug Administration approved buprenorphine-naloxone (Suboxone) sublingual tablets as an opioid dependence treatment available for use outside traditionally licensed opioid treatment programs. The NIDA Center for [...]

Plus d'info

Ajouter à la sélection

Lien externe

Community treatment programs take up buprenorphine

P. P. CASADONTE ; G. F. KOLODNER ; T. HORTON ; MCMURPHY S. | 2004
Dans Science and Practice Perspectives (Vol.2, n°2, August 2004) Article : Périodique

Clinicians have been working out ways to incorporate buprenorphine into their treatment models. Representatives of three addiction treatment programs - a Veterans Affairs methadone clinic, a group of outpatient mental health centers, and a natio[...]

Plus d'info

Ajouter à la sélection

Lien externe

Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation

E. D. COLLINS ; T. HORTON ; K. REINKE ; L. AMASS ; E. V. NUNES | 2007
Dans Journal of Substance Abuse Treatment (Vol.32, n°2, March 2007) Article : Périodique

For opioid-dependent patients, the need for detoxification has been a barrier to entry into long-term residential treatment. This report describes a retrospective observational cohort study with the first 38 opioid-dependent patients entering Fi[...]

Plus d'info

Ajouter à la sélection